Meeting News CoverageVideo

VIDEO: Midostaurin could fill ‘major unmet medical need’ in FLT3-mutated AML

ORLANDO, Fla. — Timothy Graubert, MD, reacts to study results presented during the plenary session at the ASH Annual Meeting and Exposition that demonstrated the efficacy of midostaurin in FLT3-mutated acute myeloid leukemia. The findings represent “a major advance” in AML, Graubert said.

ORLANDO, Fla. — Timothy Graubert, MD, reacts to study results presented during the plenary session at the ASH Annual Meeting and Exposition that demonstrated the efficacy of midostaurin in FLT3-mutated acute myeloid leukemia. The findings represent “a major advance” in AML, Graubert said.

    See more from ASH Annual Meeting and Exposition